Heptares is a clinical-stage company creating novel medicines targeting G protein-coupled receptors (GPCRs), a superfamily of receptors linked to a wide range of human diseases. Our proprietary StaR® technology and structure-based drug design (SBDD) capabilities are enabling us to build an exciting pipeline of new medicines with potential to transform the treatment of Alzheimer’s disease, schizophrenia, cancer, migraine, metabolic disease, and other indications. Our ability to address highly validated, yet historically undruggable, GPCRs has also attracted multiple pipeline and technology partners including Allergan, AstraZeneca, Kymab, Morphosys, Pfizer and Teva.

Heptares is a wholly owned subsidiary of Sosei Group Corporation.

Latest News

Nov 30, 2016
Heptares to Acquire G7 Therapeutics to Extend Leadership in GPCR-Focused Drug Discovery and Development
Nov 10, 2016
Jitsubo and Heptares Therapeutics to develop novel GPCR-targeting peptide candidates for severe gastro-intestinal disorders

Dec 4-7, 2016
Asian Crystallographic Association
Hanoi, Vietnam
Presenting: Andy Dore

Jan 9-12, 2017
JPMorgan Healthcare Conference
San Francisco, CA, USA
Attending: Barry Kenny, Ali Jazayeri

© 2012-2016 Heptares Therapeutics